VTX-802

About us Our DNA Board members Our leadership Partners Pipeline VTX-PID – AAV-NAbs Positive Patients VTX–806 – Cerebrotendinous Xanthomatosis VTX-802 & VTX-803 – PFIC VTX-801 – Wilson’s disease VTX-801 – GATEWAY Clinical Trial Investors News Events Patients & Families Patient’s Stories Patient advocacy Patient & Families ressources Compassionate Use and Expanded Access Work at Vivet Our DNA Board members Our leadership Partners VTX-PID – AAV-NAbs Positive Patients VTX–806 – Cerebrotendinous Xanthomatosis VTX-802 & VTX-803 – PFIC VTX-801 – Wilson’s disease VTX-801 – GATEWAY Clinical Trial Patient’s Stories Patient advocacy Patient & Families ressources Compassionate Use and Expanded Access About us Our DNA Board members Our leadership Partners Pipeline VTX-PID – AAV-NAbs Positive Patients VTX–806 – Cerebrotendinous Xanthomatosis VTX-802 & VTX-803 – PFIC VTX-801 – Wilson’s disease VTX-801 – GATEWAY Clinical Trial Investors News Events Patients & Families Patient’s Stories Patient advocacy Patient & Families ressources Compassionate Use and Expanded Access Work at Vivet Our DNA Board members Our leadership Partners VTX-PID – AAV-NAbs Positive Patients VTX–806 – Cerebrotendinous Xanthomatosis VTX-802 & VTX-803 – PFIC VTX-801 – Wilson’s disease VTX-801 – GATEWAY Clinical Trial Patient’s Stories Patient advocacy Patient & Families ressources Compassionate Use and Expanded Access Paris, 6th May 2026 – At the Annual Congress of the American Society of Gene & Cell Therapy (ASGCT), Vivet Therapeutics will present translational modeling data supporting the ability of its proprietary VTX-PID imlifidase formulation to enable AAV gene therapy in NAb-positive subjects : “Modeling of VTX-PID-driven AAV3B Neutralizing Antibody Depletion Expands Treatable Populations Across Gene Therapy Platforms : From Mechanism and Clinical data to Prediction”, presented Tuesday 12th , poster 1396 at the MCEC Exhibit and Poster Hall (Halls B2-C, Exhibit Level). Our data help de-risk and refine assumptions for any systemic gene therapy program by quantifying how realistic different scenarios are for achieving optimal positive predictive outcomes before treating patients with VTX-PID. For any patient-centric organization, these results are highly encouraging, underscoring the potential of our translational model to optimize positive predictive outcomes, enrich for responders, and ultimately expand access to AAV gene therapy. Vivet Therapeutics remains committed to advancing innovative therapies and supporting the gene therapy community’s progress toward greater patient access and improved clinical outcomes with VTX-PID ownership across the CMC package, including manufacturing process, non-clinical package & full clinical PK/PB model from Phase 1 dataset. Our DNA Board members Our team Partners Our DNA Board members Our team Partners VTX-PID – AAV-NAbs Positive Patients VTX – 806 – Cerebrotendinous Xanthomatosis VTX-802 & VTX-803 – PFIC VTX-801 – Wilson’s disease VTX-801 – GATEWAY Clinical Trial VTX-PID – AAV-NAbs Positive Patients VTX – 806 – Cerebrotendinous Xanthomatosis VTX-802 & VTX-803 – PFIC VTX-801 – Wilson’s disease VTX-801 – GATEWAY Clinical Trial Patient stories Patient advocacy Patient & Families ressources Compassionate Use and Expanded Access Patient stories Patient advocacy Patient & Families ressources Compassionate Use and Expanded Access News Events Investors Work at Vivet Contact News Events Investors Work at Vivet Contact Vivet Therapeutics Cookie Policy Vivet Therapeutics Privacy Policy

Vivet’s VTX-806 is an adeno-associated virus (AAV) vector gene therapy that reinstates CYP27A1 gene activity. Image Credit: Anusorn Nakdee / Shutterstock. The French Government has awarded a €4.9m ($5.3m) grant to Paris-based Vivet Therapeutics to develop VTX-806, a gene therapy to treat a rare condition that leads to the accumulation of cholesterol in nerve cells called cerebrotendinous xanthomatosis (CTX). The funding is part of the France Health Innovation Plan 2023 under the acceleration strategy of Biotherapies – Bioproduction in innovative therapies. The funding is operated by French investment bank Bpifrance and will be disbursed over three years, as per a 1 February press release. Vivet is developing gene therapies for different rare disorders and has a partnership with Pfizer , wherein the latter owns 15% equity in the company. VTX-806 is an adeno-associated virus (AAV) vector gene therapy that reinstates CYP27A1 gene activity. The therapy is being developed to stop or reverse disease progression over the long term, or to potentially cure CTX. CTX is a rare autosomal recessive genetic disorder caused by an abnormality in the CYP27A1 gene. The gene is responsible for producing mitochondrial enzyme sterol 27-hydroxylase enzyme, responsible for converting cholesterol into a bile acid. See Also: Almirall and Microsoft partner for dermatological drug development Takeda and Protagonist sign rusfertide development deal If untreated, CTX can cause progressive neurologic problems such as seizures, cognitive impairment, and ataxia. Current disease treatment includes oral bile acid replacement therapy and treatment with chenodeoxycholic acid to normalise the production of cholestanol. Vivet’s lead candidate, VTX-801, is a gene therapy for Wilson’s disease being developed with Pfizer . The AAV vector gene therapy targets the ATP7B gene, responsible for causing the condition. It is currently being investigated in an open-label Phase I/II GATEWAY trial (NCT04537377), that has a clinical readout expected by the end of the year. The study’s endpoint is to assess the safety and tolerability of VTX-801 at 52 weeks after a single infusion. Additional endpoints include changes in disease-related biomarkers, including free serum copper and serum ceruloplasmin activity, as well as radiocopper-related parameters and VTX-801 responder status to allow standard-of-care withdrawal. Other therapies in Vivet’s preclinical pipeline include VTX-804 for the treatment of a rare neurological disorder, citrullinemia type 1, along with VTX-802 and VTX-803 for the treatment of progressive familial intrahepatic cholestasis (PFIC) – a set of rare genetic disorders. In 2021, US-based Mirum Pharmaceuticals acquired development and commercialisation rights for VTX-802 and VTX-803. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy